©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Transplant. Dec 24, 2016; 6(4): 665-674
Published online Dec 24, 2016. doi: 10.5500/wjt.v6.i4.665
Published online Dec 24, 2016. doi: 10.5500/wjt.v6.i4.665
Overview of the progress on haploidentical hematopoietic transplantation
Nosha Farhadfar, William J Hogan, Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, United States
Author contributions: All authors contributed to drafting, revision and final approval of the article.
Conflict-of-interest statement: The authors declare no conflicts of interest regarding this manuscript.
Correspondence to: William J Hogan, MBBCh, MRCPI, Division of Hematology, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, United States. hogan.william@mayo.edu
Telephone: +1-507-2842017 Fax: +1-507-2664972
Received: July 19, 2016
Peer-review started: July 21, 2016
First decision: September 5, 2016
Revised: September 28, 2016
Accepted: October 22, 2016
Article in press: October 24, 2016
Published online: December 24, 2016
Processing time: 147 Days and 20.3 Hours
Peer-review started: July 21, 2016
First decision: September 5, 2016
Revised: September 28, 2016
Accepted: October 22, 2016
Article in press: October 24, 2016
Published online: December 24, 2016
Processing time: 147 Days and 20.3 Hours
Core Tip
Core tip: Over the past decade, haploidentical donors have emerged as a viable alternate graft source for patients without a HLA-matched donor. Several strategies including graft manipulation, conditioning regimen optimization and better graft-versus-host disease control have significantly improved the outcomes of haploidentical hematopoietic stem cell transplant (HSCT). Here, we summarize some of the recent advances in the field of haploidentical HSCT in adults.